The estimated Net Worth of Monica Forbes is at least $1.09 Million dollars as of 2 March 2023. Ms. Forbes owns over 371,125 units of Sesen Bio stock worth over $380,500 and over the last 5 years she sold SESN stock worth over $36,499. In addition, she makes $675,245 as Chief Financial Officer and Treasurer at Sesen Bio.
Monica has made over 2 trades of the Sesen Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 371,125 units of SESN stock worth $218,964 on 2 March 2023.
The largest trade she's ever made was exercising 371,125 units of Sesen Bio stock on 2 March 2023 worth over $218,964. On average, Monica trades about 72,165 units every 2 days since 2019. As of 2 March 2023 she still owns at least 603,968 units of Sesen Bio stock.
You can see the complete history of Ms. Forbes stock trades at the bottom of the page.
Monica Forbes serves as Chief Financial Officer, Treasurer of the Company. Ms. Forbes previously served as a finance consultant to the Company from April 2019 through July 2019, at which time she joined the Company as our Vice President, Finance since August 1, 2019. From July 2018 to April 2019, Ms. Forbes served as the Vice President and Chief Financial Officer of Nalpropion Pharmaceuticals, Inc. Prior to that Ms. Forbes served as Vice President and acting Chief Financial Officer of Orexigen Therapeutics, Inc. from February 2018 until Nalpropion’s acquisition of Orexigen in July 2018, Senior Director of Financial Planning and Analysis (FP&A) of Orexigen from October 2016 to February 2018, and Director of FP&A from October 2014 to October 2016. Ms. Forbes holds a B.S. in Business Administration from San Diego State University.
As the Chief Financial Officer and Treasurer of Sesen Bio, the total compensation of Monica Forbes at Sesen Bio is $675,245. There are 3 executives at Sesen Bio getting paid more, with Thomas Cannell having the highest compensation of $1,404,240.
Monica Forbes is 44, she's been the Chief Financial Officer and Treasurer of Sesen Bio since 2020. There are 14 older and 2 younger executives at Sesen Bio. The oldest executive at Sesen Bio Inc. is Dr. Glen C. MacDonald, 70, who is the Chief Technology Officer.
Monica's mailing address filed with the SEC is C/O SESEN BIO, INC, 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes, and Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Sesen Bio executives and other stock owners filed with the SEC include: